Results 121 to 130 of about 12,408 (251)
Advanced Healthcare Materials, Volume 15, Issue 23, 19 June 2026.ABSTRACT The ascent of novel alternative methods in drug development spotlights the dual needs for improved biological fidelity to in vivo, along with reproducibility, especially in regulatory applications. The need for pre‐clinical models of patient‐derived endometriosis lesions motivates the development of a vascularizable, completely synthetic ...
Lauren Pruett +7 more
wiley +1 more source
A Modular and Programmable Cas13d Platform for RNA Single Nucleotide Variant Detection
Advanced Science, Volume 13, Issue 32, 9 June 2026.A scenario‐guided Cas13d platform enables configurable single nucleotide variant ribonucleic acid diagnostics through rule‐based guide design and ribonucleic acid binding domain engineering, supporting amplification‐free ultrasensitive detection and amplification‐coupled robust detection for accurate mutation classification in clinical tumor specimens.
Zeyu Wang +8 more
wiley +1 more source
Advanced Science, Volume 13, Issue 33, 15 June 2026.This study elucidates the mechanisms of subcellular multidimensional collapse in exhausted T cells. By specifically targeting the nucleus, mitochondria, and endoplasmic reticulum, strategic interventions can effectively remodel the compromised organelle network. This integrated approach drives comprehensive T cell resuscitation, ultimately establishing
Mingxing Wang +9 more
wiley +1 more source
Residue Packing Conditions in Bovine Pancreatic Ribonuclease-S [PDF]
, 1991 An attempt is made to identify the exposed and Buried residue sites of Bovine Pancreatic Ribonuclease-S through the concept of residue packing. The crystaliographic data of the protein is used to carry out four kinds of packing studies.
Bhaskaran, R
core
Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects
Advanced Science, Volume 13, Issue 36, 29 June 2026.Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu +6 more
wiley +1 more source
Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.miR‐4660 was found to be downregulated in exosomes derived from SMMC‐OPN cells, a stable HCC cell line that overexpresses OPN. LGALS3BP has been identified as a direct target of miR‐4660, with its expression levels elevated in both SMMC‐OPN cells and their secreted exosomes.
Cuihua Liu +9 more
wiley +1 more source
ChemNanoMat, Volume 12, Issue 6, June 2026.Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo +3 more
wiley +1 more source
Alterations of circulating innate lymphoid cells in recent‐onset type 1 diabetes
Clinical &Translational Immunology, Volume 15, Issue 6, 2026.Circulating innate lymphoid cells (ILC) in patients with recent‐onset type 1 diabetes (T1D) show a chronic activation and a primed phenotype, with overexpression of HLA Class II (ILC1 and ILCP) and dysregulation of costimulatory and migratory mRNA transcripts. Glucose and cytokines (IL‐1β) mediate circulating ILC activation and HLA Class II expression.
Ariadna Roig +5 more
wiley +1 more source